A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.On November 14, MPM BioImpact reported in a U.S. Securities and Exchange Commission filing that it sold out its MoonLake Immunotherapeutics position, reducing exposure by $14.8 million in the third quarter.What happenedAccording to a U.S. Securities and Exchange Commission filing dated November 14, MPM BioImpact fully sold its stake in MoonLake Immunotherapeutics (MLTX +1.40%) during the third qu ...